According to filings with the U.S. Securities and Exchange Commission, Unlearn.ai is raising up to $49,999,956.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Charles Fisher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Unlearn.ai
Enrollment challenges and timeline delays plague clinical trials. External controls can help solve these problems, but are typically unreliable. TwinRCTs generate reliable evidence in a fraction of the time. TwinRCTs combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials. Clinical trials with smaller control groups are more attractive to patients. TwinRCTs reach enrollment targets faster because they require fewer patients. TwinRCTs provide reliable evidence suitable for pivotal clinical trials.

To learn more about Unlearn.ai, visit http://www.unlearn.ai/

Contact:
Charles Fisher, President and Chief Executive Officer
415-455-3005
https://www.linkedin.com/in/drckf/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.